Q32 Bio

QTTB · NASDAQ

$8.62+$0.83 (+10.65%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $7.79

QTTB analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $40.12 (+365.4% upside)

Low: $29.29
Now: $8.62
High: $61.95

Upgrades and downgrades

The latest rating actions, newest first

QTTB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Leerink Partners	Oct 12, 2026	Initiates	Outperform	$40.00	0%
Jefferies	Sep 28, 2026	Initiates	Buy	$29.00	29%
Morgan Stanley	Aug 24, 2026	Initiates	Overweight	$34.00	57%
HC Wainwright & Co.	Jul 28, 2026	Maintains	Buy	$13.00 → $36.00	40%
Oppenheimer	Jul 13, 2026	Maintains	Outperform	$20.00 → $40.00	45%
Wells Fargo	Jul 13, 2026	Upgrade	Equal-Weight → Overweight	$66.00	54%
Mizuho	May 22, 2026	Initiates	Outperform	$14.00	54%
Cantor Fitzgerald	May 18, 2026	Initiates	Overweight	—	—
HC Wainwright & Co.	May 5, 2026	Maintains	Buy	$13.00	40%
HC Wainwright & Co.	Feb 25, 2026	Initiates	Buy	$13.00	40%

The case for and against

Updated May 30, 2025

Bull case

Q32 Bio Inc demonstrates a strong outlook due to the promising data from its lead product candidate, bempikibart, which has shown an attractive pharmacokinetic/pharmacodynamic profile and improved tolerability in clinical trials for atopic dermatitis and alopecia areata. Notably, the drug achieved a 16% reduction in the severity of alopecia areata in a Phase 2 post-hoc analysis and reported a 76% improvement in the average Eczema Area and Severity Index (EASI) score, underscoring its potential effectiveness compared to existing treatments. Furthermore, the company has increased the probability of success for its alopecia areata opportunity to 75%, reflecting heightened confidence in its therapeutic candidates amidst a growing market for novel biologics targeting autoimmune and inflammatory conditions.

Bear case

Q32 Bio Inc is experiencing a negative outlook due to several fundamental issues, including modest efficacy signals in their lead product candidates that fall significantly below market expectations. The company has recently faced disappointing topline results from critical Phase II studies, leading to concerns about the applicability of their mechanism of action in targeted indications, which further hampers investor confidence. Additionally, there are ongoing concerns regarding cash flow and the potential need for the company to raise funds in the market before achieving profitability, compounding the risks associated with its research and development endeavors.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.